Early extracorporeal life support (ECLS) does not improve survival in patients with acute myocardial infarction complicated by cardiogenic shock who are scheduled for early revascularization, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Vertex may face another battle in the U.K. over the value of its cystic fibrosis medicines
Once again, Vertex Pharmaceuticals and a U.K. government agency are at odds over the value of life-saving cystic fibrosis medicines. In draft guidance published late